- Home
- NXN vs IFRX Comparison
NXN vs IFRX Comparison
Compare NXN & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- IFRX
- Stock Information
- Founded
- NXN 1992
- IFRX 2007
- Country
- NXN United States
- IFRX Germany
- Employees
- NXN N/A
- IFRX N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- IFRX Health Care
- Exchange
- NXN Nasdaq
- IFRX Nasdaq
- Market Cap
- NXN 47.3M
- IFRX 53.5M
- IPO Year
- NXN N/A
- IFRX 2017
- Fundamental
- Price
- NXN $11.95
- IFRX $1.18
- Analyst Decision
- NXN
- IFRX Strong Buy
- Analyst Count
- NXN 0
- IFRX 5
- Target Price
- NXN N/A
- IFRX $7.40
- AVG Volume (30 Days)
- NXN 9.7K
- IFRX 486.5K
- Earning Date
- NXN 01-01-0001
- IFRX 11-07-2025
- Dividend Yield
- NXN 4.23%
- IFRX N/A
- EPS Growth
- NXN N/A
- IFRX N/A
- EPS
- NXN 0.24
- IFRX N/A
- Revenue
- NXN N/A
- IFRX $191,224.00
- Revenue This Year
- NXN N/A
- IFRX N/A
- Revenue Next Year
- NXN N/A
- IFRX $1,216.24
- P/E Ratio
- NXN $48.42
- IFRX N/A
- Revenue Growth
- NXN N/A
- IFRX 54.36
- 52 Week Low
- NXN $10.64
- IFRX $0.71
- 52 Week High
- NXN $12.45
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- NXN 47.88
- IFRX 44.35
- Support Level
- NXN $11.96
- IFRX $1.13
- Resistance Level
- NXN $12.06
- IFRX $1.44
- Average True Range (ATR)
- NXN 0.08
- IFRX 0.14
- MACD
- NXN -0.02
- IFRX -0.04
- Stochastic Oscillator
- NXN 28.12
- IFRX 16.00
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.